News
ASRT
0.8859
+5.09%
0.0429
Assertio Therapeutics Announces Leadership Changes and Board Addition
TipRanks · 4d ago
ASSERTIO HOLDINGS, INC. APPOINTS MARK REISENAUER TO ITS BOARD OF DIRECTORS
Reuters · 4d ago
Press Release: Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
Dow Jones · 4d ago
Positive Clinical Results and Market Potential Drive Buy Rating for Assertio Therapeutics
TipRanks · 5d ago
Assertio Holdings Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on Assertio Holdings, Maintains $4 Price Target
Benzinga · 6d ago
Promising Buy Rating for Assertio Therapeutics Backed by Positive ROLVEDON Trial Results and Market Potential
TipRanks · 6d ago
Weekly Report: what happened at ASRT last week (1209-1213)?
Weekly Report · 6d ago
Executive reshuffles: JPM, QCOM, DVN and LTC
Seeking Alpha · 12/14 20:54
Assertio Holdings announces results of Rolvedon injection study
TipRanks · 12/13 13:05
Assertio Announces Results Of A Clinical Trial Investigating The Utility Of Rolvedon Injection When Dosed The Same Day Of Chemotherapy For Patients With Early Stage Breast Cancer
Benzinga · 12/13 13:03
ASSERTIO ANNOUNCES RESULTS OF ROLVEDON® (EFLAPEGRASTIM-XNST) INJECTION SAME-DAY DOSING CLINICAL STUDY
Reuters · 12/13 13:00
ASSERTIO HOLDINGS INC - ROLVEDON SHOWS 1.8 DAYS TO NEUTROPHIL COUNT RECOVERY
Reuters · 12/13 13:00
Assertio Holdings Appoints Paul Schwichtenberg as Chief Transformation Officer and Mary Pietryga as Chief Commercial Officer
Barchart · 12/12 17:24
Lake Street Sticks to Its Buy Rating for Assertio Therapeutics (ASRT)
TipRanks · 12/12 13:56
Assertio Holdings appoints Schwichtenberg as CTO, Pietrya as CCO
TipRanks · 12/12 13:11
*Assertio Holdings: Pietryga Responsible for Sales, Marketing and Comml Access >ASRT
Dow Jones · 12/12 13:08
*Assertio Holdings: Pietryga Replaces Schwichtenberg >ASRT
Dow Jones · 12/12 13:08
*Assertio Holdings: Pietryga Named Chief Comml Officer From Dec 16 >ASRT
Dow Jones · 12/12 13:07
*Assertio: Schwichtenberg to Identify Synergies, Innovative Strategies, New Rev Streams >ASRT
Dow Jones · 12/12 13:02
More
Webull provides a variety of real-time ASRT stock news. You can receive the latest news about Assertio Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About ASRT
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).